On the public citation graph
Pharmaceutical Patent Challenges: Company Strategies and Litigation Outcomes
0 signed · 71 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/mde.1356openalex-snapshot
Generic competition and market exclusivity periods in pharmaceuticals
inferredcites →https://doi.org/10.1016/j.jhealeco.2010.09.004openalex-snapshot
The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms
inferredcites →https://doi.org/10.1016/j.jhealeco.2012.01.004openalex-snapshot
Evergreening, patent challenges, and effective market life in pharmaceuticals
inferredcites →https://doi.org/10.1016/j.jhealeco.2016.01.012openalex-snapshot
Innovation in the pharmaceutical industry: New estimates of R&D costs
inferredcites →https://doi.org/10.1080/13571516.2011.584423openalex-snapshot
Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation
inferredcites →https://doi.org/10.1080/13571516.2015.1045744openalex-snapshot
Do “Reverse Payment” Settlements Constitute an Anticompetitive Pay-for-Delay?
inferredcites →https://doi.org/10.1093/oxfordhb/9780199742998.013.0008openalex-snapshot
Pricing and Reimbursement in US Pharmaceutical Markets
inferredcites →https://doi.org/10.1111/j.1740-1461.2011.01235.xopenalex-snapshot
When Do Generics Challenge Drug Patents?
inferredcites →https://doi.org/10.1126/science.1176116openalex-snapshot
Balancing Innovation and Access: Patent Challenges Tip the Scales
inferredcites →https://doi.org/10.1126/science.1235857openalex-snapshot
Drug Patents at the Supreme Court
inferredcites →https://doi.org/10.1257/aer.20131176openalex-snapshot
Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials
inferredcites →https://doi.org/10.1377/hlthaff.20.5.11openalex-snapshot
Is Technological Change In Medicine Worth It?
inferredcites →https://doi.org/10.1377/hlthaff.2009.1056openalex-snapshot
The Benefits From Giving Makers Of Conventional ‘Small Molecule’ Drugs Longer Exclusivity Over Clinical Trial Data
inferredcites →https://doi.org/10.1377/hlthaff.2013.0862openalex-snapshot
Regulatory And Cost Barriers Are Likely To Limit Biosimilar Development And Expected Savings In The Near Future
inferredcites →https://doi.org/10.1377/hlthaff.2014.1029openalex-snapshot
Decline In Economic Returns From New Drugs Raises Questions About Sustaining Innovations
inferredcites →https://doi.org/10.1377/hlthaff.2014.1047openalex-snapshot
The Roles Of Patents And Research And Development Incentives In Biopharmaceutical Innovation
inferredcites →https://doi.org/10.2165/00019053-200220003-00002openalex-snapshot
Returns on Research and Development for 1990s New Drug Introductions
inferredcites →https://doi.org/10.3111/13696998.2013.873723openalex-snapshot
Recent trends in brand-name and generic drug competition
inferredcites →https://doi.org/10.7208/chicago/9780226551791.001.0001openalex-snapshot
Measuring the Gains from Medical Research
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.3748158openalex-extracted
One product, many patents: Imperfect intellectual property rights in the pharmaceutical industry
inferred← citeshttps://doi.org/10.1001/jamainternmed.2017.4329openalex-snapshot
Determinants of Market Exclusivity for Prescription Drugs in the United States
inferred← citeshttps://doi.org/10.1002/joom.1175openalex-snapshot
The impact of chief risk officer appointments on firm risk and operational efficiency
inferred← citeshttps://doi.org/10.1007/978-3-031-29436-5_7openalex-snapshot
The Impact of Test Data Exclusivity on Abbreviated New Drug Applications in the United States
inferred← citeshttps://doi.org/10.1007/978-981-15-8214-1_15openalex-snapshot
A Glance to the Patent World of Probiotics
inferred← citeshttps://doi.org/10.1007/s10198-022-01510-5openalex-snapshot
Dividend policy issues in the European pharmaceutical industry: new empirical evidence
inferred← citeshttps://doi.org/10.1007/s43441-025-00831-wopenalex-snapshot
Unlocking Generic Market Access: A Retrospective Analysis of USFDA Paragraph IV Filings (2020–2024)
inferred← citeshttps://doi.org/10.1080/03639045.2021.1935997openalex-snapshot
Incentives to promote the US pharmaceutical innovation: empirical research based on the case of Epogen
inferred← citeshttps://doi.org/10.1080/13543776.2022.2145885openalex-snapshot
Exploring drug patent linkage and the first ANDA litigation in China
inferred← citeshttps://doi.org/10.1080/13696998.2016.1176578openalex-snapshot
Updated trends in US brand-name and generic drug competition
inferred← citeshttps://doi.org/10.1080/13696998.2021.1952795openalex-snapshot
Continuing trends in U.S. brand-name and generic drug competition
inferred← citeshttps://doi.org/10.1093/oso/9780197630914.001.0001openalex-snapshot
The Economics of Innovation and Intellectual Property
inferred← citeshttps://doi.org/10.1093/oso/9780197630914.003.0001openalex-snapshot
Innovation and Intellectual Property
inferred← citeshttps://doi.org/10.1093/oso/9780197630914.003.0002openalex-snapshot
What Is Innovation?
inferred← citeshttps://doi.org/10.1093/oso/9780197630914.003.0003openalex-snapshot
Supply and Demand for Innovation
inferred← citeshttps://doi.org/10.1093/oso/9780197630914.003.0004openalex-snapshot
Appropriation Mechanisms
inferred← citeshttps://doi.org/10.1093/oso/9780197630914.003.0005openalex-snapshot
Innovation and Competition in Firms
inferred← citeshttps://doi.org/10.1093/oso/9780197630914.003.0006openalex-snapshot
Returns to R&D and Innovation
inferred← citeshttps://doi.org/10.1093/oso/9780197630914.003.0008openalex-snapshot
Innovation Strategy
inferred← citeshttps://doi.org/10.1093/oso/9780197630914.003.0009openalex-snapshot
Innovation and Economic Growth
inferred← citeshttps://doi.org/10.1093/oso/9780197630914.003.0011openalex-snapshot
Patents, Utility Models, Design Rights, and Plant Breeder Rights
inferred← citeshttps://doi.org/10.1093/oso/9780197630914.003.0012openalex-snapshot
Trademarks and Brands
inferred← citeshttps://doi.org/10.1093/oso/9780197630914.003.0014openalex-snapshot
Alternatives to Intellectual Property
inferred← citeshttps://doi.org/10.1093/oso/9780197630914.003.0015openalex-snapshot
Intellectual Property Rights and Economic Development
inferred← citeshttps://doi.org/10.1093/oso/9780197630914.003.0016openalex-snapshot
Patents and Pharmaceuticals
inferred← citeshttps://doi.org/10.1093/oso/9780197630914.003.0017openalex-snapshot
Software, Business and Financial Methods, Open Source, and Artificial Intelligence
inferred← citeshttps://doi.org/10.1093/oso/9780197630914.003.0018openalex-snapshot
Strategic Patenting, Patent Portfolio Races, and Patent Thickets
inferred← citeshttps://doi.org/10.1093/oso/9780197630914.003.0019openalex-snapshot
Patent Litigation and Enforcement
inferred← citeshttps://doi.org/10.1093/oso/9780197630914.003.0020openalex-snapshot
The Sharing and Exchange of Patents
inferred← citeshttps://doi.org/10.1093/oso/9780197630914.003.0021openalex-snapshot
Technology Standards and Standard Essential Patents
inferred← citeshttps://doi.org/10.1093/oso/9780197630914.005.0001openalex-snapshot
Mathematics and Statistics
inferred← citeshttps://doi.org/10.1093/oso/9780197630914.005.0002openalex-snapshot
List of Abbreviations
inferred← citeshttps://doi.org/10.1109/access.2018.2859052openalex-snapshot
Legal Decision Support: Exploring Big Data Analytics Approach to Modeling Pharma Patent Validity Cases
inferred← citeshttps://doi.org/10.1111/ijmr.12354openalex-snapshot
Divide and conquer: Relating patent quality and value in a conceptual framework based on a systematic review
inferred← citeshttps://doi.org/10.1177/0020731418822237openalex-snapshot
Does the Patent Linkage System Prolong Effective Market Exclusivity? Recent Evidence From the Korea-U.S. Free Trade Agreement in Korea
inferred← citeshttps://doi.org/10.1186/s12992-018-0423-0openalex-snapshot
Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States
inferred← citeshttps://doi.org/10.1186/s12992-022-00826-4openalex-snapshot
What is the impact of intellectual property rules on access to medicines? A systematic review
inferred← citeshttps://doi.org/10.1257/pol.20200703openalex-snapshot
Investing in Ex Ante Regulation: Evidence from Pharmaceutical Patent Examination
inferred← citeshttps://doi.org/10.12688/wellcomeopenres.14947.1openalex-snapshot
Ideation and implementation of an open science drug discovery business model – M4K Pharma
inferred← citeshttps://doi.org/10.1371/journal.pone.0311238openalex-snapshot
Needle in a haystack: Harnessing AI in drug patent searches and prediction
inferred← citeshttps://doi.org/10.22201/fca.24488410e.2018.1717openalex-snapshot
Valuation of an investment project in research and development in the pharmaceutical industry
inferred← citeshttps://doi.org/10.3386/w27579openalex-snapshot
Investing in Ex Ante Regulation: Evidence from Pharmaceutical Patent Examination
inferred← citeshttps://doi.org/10.6084/m9.figshare.19607472openalex-snapshot
Additional file 1 of What is the impact of intellectual property rules on access to medicines? A systematic review
inferred← citeshttps://doi.org/10.6084/m9.figshare.19607475openalex-snapshot
Additional file 2 of What is the impact of intellectual property rules on access to medicines? A systematic review
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.